Document Detail


Coronary stenting is associated with an acute increase in plasma myeloperoxidase in stable angina patients but not in patients with acute myocardial infarction.
MedLine Citation:
PMID:  19712859     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Myeloperoxidase (MPO) has emerged as a critical mediator in the physiopathology of atherosclerosis from plaque formation and growth until destabilization and rupture leading to acute coronary syndrome (ACS). Using coronary stenting as a model of plaque injury, we aimed to determine the evolution of systemic MPO levels following coronary stenting in stable angina patients and in patients with acute myocardial infarction (AMI). METHODS: Plasma levels of MPO, lactoferrin, interleukin (IL)-6, C-reactive protein and PMN counts were assessed in 13 patients with Non-ST-elevation myocardial infarction (NSTEMI) (Group A) and in 29 patients with stable angina pectoris (Group B), undergoing coronary stenting. Serial blood samples were taken before angioplasty (baseline) and at 1, 6 and 24 h following initial balloon inflation. RESULTS: Following angioplasty, the overall plasma MPO levels significantly increased at 1 h in group B (120.5+/-79.0 to 166+/-79.5, p=0.003) but not in group A (121+/-63.4 to 124.7+/-76.9, p=0.753). In Group B, the increase in MPO levels at 1 h were significantly higher in the presence of complex lesions compared to patients with simple lesions (p=0.023). Lactoferrin levels showed no change over time except for a significant decrease at 6 h in group B. CONCLUSIONS: In stable angina patients, coronary stenting is associated with an acute and transient increase in plasma MPO levels, but not in lactoferrin levels, with an enhanced response in the presence of complex lesions. In contrast, we observed no changes in plasma MPO and lactoferrin levels following stenting in patients with AMI. Given its pro-inflammatory properties, the potential implication of MPO release on clinical outcome in stable patients undergoing stenting needs further investigation.
Authors:
Adel Aminian; Karim Zouaoui Boudjeltia; Sajida Babar; Pierre Van Antwerpen; Pascal Lefebvre; Vincent Crasset; Attilio Leone; Jean Ducobu; Alain Friart; Michel Vanhaeverbeek
Related Documents :
16263349 - Short- and long-term outcomes of the titanium-no stent registry.
16390649 - Aorfix stent graft for abdominal aortic aneurysms reduces the risk of proximal type 1 e...
9786389 - Low restenosis rate in lesions of the left anterior descending coronary artery with ste...
20236209 - The paclitaxel-eluting coroflex stent study ii (pecops ii) acute and 6-month clinical a...
12194339 - 3d dosimetry study of 188re liquid balloon for intravascular brachytherapy using bang p...
17437849 - Diamond-like carbon coatings on ureteral stents--a new strategy for decreasing the form...
22050029 - Impact of electrocardiographic interpretability on outcome in patients referred for str...
6238989 - Acute coronary artery occlusion during percutaneous transluminal coronary angioplasty t...
1869989 - Severe hypoxemia secondary to acute sternal infarction in sickle cell anemia.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2009-06-16
Journal Detail:
Title:  European journal of internal medicine     Volume:  20     ISSN:  1879-0828     ISO Abbreviation:  Eur. J. Intern. Med.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-28     Completed Date:  2010-01-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9003220     Medline TA:  Eur J Intern Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  527-32     Citation Subset:  IM    
Copyright Information:
2009 European Federation of Internal Medicine.
Affiliation:
Division of Cardiology, Tivoli University Hospital, La Louvi??re, Belgium. adaminian@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angina Pectoris / enzymology*,  therapy
Angioplasty, Transluminal, Percutaneous Coronary*
Biological Markers / blood
C-Reactive Protein / metabolism
Cohort Studies
Female
Humans
Interleukin-6 / blood
Lactoferrin / blood
Male
Middle Aged
Myocardial Infarction / enzymology*,  therapy
Neutrophil Activation / physiology
Peroxidase / blood*
Stents*
Time Factors
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Interleukin-6; 0/Lactoferrin; 9007-41-4/C-Reactive Protein; EC 1.11.1.7/Peroxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differences in cardiovascular mortality in smokers, past-smokers and non-smokers: findings from the ...
Next Document:  Analysis of temporal artery biopsies in an 18-year period at a community hospital.